Mendoza PE

Language: Spanish
References: 10
Page: 375-378
PDF size: 63.07 Kb.

ABSTRACT

High-Density Lipoprotein Cholesterol (HDL-C) is an important predictor of risk for acute coronary events, under epidemiologic and intervention evidence. Subjects with low levels of HDL-C (‹ 40 mg/dL) have a significantly increased rate for acute coronary events than subjects with higher levels of HDL-C (› 40 mg/dL). Nevertheless, 40% of acute coronary events occur in subjects with HDL-C › 40 mg/dL with normal Low-Density Lipoprotein Cholesterol levels (LDL-C). Therefore, several intervention studies have shown than modest increases in HDL-C concentrations result in a significant risk reduction for acute coronary events. For this reason, in recent years, more attention has been focused on qualitative aspects of HDL particles, and now we know that these particles have various size, composition, and anti-atherogenic properties. The purpose of this review is to show changes on HDL functionality in response to lipid modifying therapy.

REFERENCES

1. Gordon D, Rifkind BM: Current concepts: high density lipoproteins- the clinical implications of recent studies. N Engl J Med 1989; 321: 1311-1315.

2. Gotto AM Jr: Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease. A working group report. Circulation 2001; 103: 2213-2218.

3. Asztalos BF, Scheafer EJ: High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003; 91(Suppl.): 12E-17E.

4. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper ChJ, Yasin M: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA 2003; 290: 2292-2300.

5. Shah PK, Kaul S, Nilsson J, Cercek B: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins. An idea whose time for testing is coming, Part I. Circulation 2001; 104: 2376-2383.

6. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Scheafer EJ: Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002; 164: 361-369.

7. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS: Change in a1 HDL concentration predicts progression in coronary artery stenosis. Atheroscler Thromb Vasc Biol 2003; 23: 847-852.

8. Guerin M, Le Goff W, Frisdal E, Schneider S, Milosavljevic D, Bruckert E: Action of ciprofibrate in type IIB hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of hihg-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 2003; 88: 3738-3746.

9. Ulloa N, Arteaga E, Bustos P, Durán-Sandoval D, Schulze K, Castro G: Sequential estrogen-progestin replacement therapy in healthy postmenopausal women: effects on cholesterol efflux capacity and key proteins regulating high-density lipoprotein levels. Metabolism 2002; 51: 1410-1417.

10. von Eckardstein A, Crook D, Elbers J, Ragoobir J, Ezeh B, Helmond F: Tibulone lowers high density lipoprotein cholesterol by increasing hepatic lipasa activity but does not impair cholesterol efflux. Clin Endocrinol 2003; 58: 49-58.